These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11044356)

  • 41. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concomitant inactivation of p53 and Chk2 in breast cancer.
    Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
    Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
    Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
    Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
    Choi DH; Lee MH; Bale AE; Carter D; Haffty BG
    J Clin Oncol; 2004 May; 22(9):1638-45. PubMed ID: 15117986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
    Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
    Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
    Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
    Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
    Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunohistochemical and molecular analysis of bax, bcl-2 and p53 genes in laryngeal squamous cell carcinomas.
    Fracchiolla NS; Capaccio P; Carboni N; Pagliari AV; Neri A; Ronchett D; Pruner G; Silvotti MG; Pignataro L; Buffa R; Broich G
    Anticancer Res; 1999; 19(2A):1043-51. PubMed ID: 10368653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The molecular pathology of hereditary breast cancer.
    Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
    Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
    Seo JH; Cho DY; Ahn SH; Yoon KS; Kang CS; Cho HM; Lee HS; Choe JJ; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Son GS; Lee JB; Koo BH
    Hum Mutat; 2004 Oct; 24(4):350. PubMed ID: 15365993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status.
    Jares P; Rey MJ; Fernández PL; Campo E; Nadal A; Muñoz M; Mallofré C; Muntané J; Nayach I; Estapé J; Cardesa A
    J Pathol; 1997 Jun; 182(2):160-6. PubMed ID: 9274525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
    Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
    Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases.
    Frankfurt OS; Robb JA; Sugarbaker EV; Villa L
    Clin Cancer Res; 1997 Mar; 3(3):465-71. PubMed ID: 9815706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.
    Bhargava V; Kell DL; van de Rijn M; Warnke RA
    Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.